medac Pharma Sponsored Webinar

Wednesday 29th May 2023

18:30 – 19:30

Learning outcomes:

  • To be aware of the licensed indications for methotrexate
  • To be aware of the differences between using subcutaneous (SC) methotrexate and oral methotrexate
  • To be able to feel comfortable initiating and monitoring SC methotrexate
  • Increase confidence of managing a switch from oral to SC methotrexate
  • To be able to manage the common side effects of methotrexate


Dr Tom King – Consultant Dermatologist, Sheffield Teaching Hospitals & Honorary Senior Lecturer,  The University of Sheffield

Emmanuel Toni – Advanced Nurse Practitioner Dermatology, PHD Research Centre for Appearance Research, UWE Bristol

This promotional webinar is initiated and funded by medac Pharma and is open to healthcare professionals only. medac Pharma products will be discussed.

Click here for prescribing information: https://www.medacpharma.co.uk/uk/app/uploads/general/medac-metoject-pen-pi.pdf

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to medac drug safety at: drugsafety@medac.de

Metoject PEN is indicated for the treatment of active rheumatoid arthritis in adult patients, polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate, moderate to severe psoriasis in adult patients who are candidates for systemic therapy, and severe psoriatic arthritis in adults and mild to moderate Crohn’s disease either alone or in combination with corticosteroids in adult patients refractory or intolerant to thiopurines. Further information can be found at: https://www.medicines.org.uk/emc/search?q=%22Metoject%22

medacuk 090/05/2024    Date of preparation: May 2024